Researcher finds the use of traditional, natural medicines offer economic benefits
For millions of people around the world being sick doesn't mean making a trip to the local pharmacy for medicines like Advil and Nyquil. Instead it means turning to the forest to provide a pharmacopeia of medicines to treat everything from tooth aches to chest pains.
But while questions persist about whether such natural remedies are as effective as their pharmacological cousins, one Harvard researcher is examining the phenomenon from a unique perspective, and trying to understand the economic benefits people receive by relying on such traditional cures.
As reported in a paper published this week in PLoS ONE, Christopher Golden, '05, a Post-Doctoral Fellow at the Harvard University Center for the Environment has found that, in the area of northwest Madagascar he studies, people annually receive between $5 and $8 in benefits by using natural medicines.
Though seemingly slight, those benefits add up to between $30 and $45 per household, Golden said, or anywhere from 43 to 63 percent of the median annual income for families in the region.
"We documented people using more than 240 different plant species to treat as many as 82 different illnesses," Golden said. "This data suggests that it can have quite an impact, financially."
It's an impact that may not be limited to Madagascar, or other regions where access to pharmaceuticals is limited.
As part of his analysis, Golden also compared the use of natural remedies with the prices that American consumers might pay if they were purchasing the pharmaceutical equivalent online where prices are typically lower than on pharmacy shelves. To his surprise, the results showed that the average American could save anywhere from 22 to 63 percent of their annual health care bill, simply by using natural medicines.
"If Americans were relying on traditional medicines as much as people in Madagascar, it could save them a major percentage of their health care expenditures," Golden said.
Golden, however, was quick to emphasize that his study only examined the economics of the natural remedies versus pharmaceuticals, not whether they were equally effective.
"What we're trying to do is account for the economic value the local floral bio-diversity provides to people in this area of Madagascar," Golden said. "We're not assuming there is a medical equivalency this study is about the perceived efficacy. The people who live in this region often have taken both pharmaceuticals and traditional medicines many times, but there is a perceived efficacy for these traditional medicines."
Measuring that perceived efficacy involved surveying 1,200 households in and around Maroantsetra, a city in the northeast corner of the island nation, to determine which natural medicines they used.
To establish the economic benefit of each natural remedy, Golden asked whether people would prefer to use the natural or pharmaceutical remedy for a given illness. If, for example, 60 percent of those asked said they preferred the traditional medicine, Golden established its value as being 60 percent of the price of its pharmaceutical cousin.
"Certainly, because there's no proof of medical equivalency between these treatments, it could easily be an over-estimation to establish these values," Golden said. "But the bio-diversity in these regions represents a huge pharmacopeia, and there are many hidden benefits to the use of these sorts of traditional medicines. These medicines aren't being improperly prescribed or mismanaged, and because they've been used for millennia, we know they're not producing any type of negative side effects."
The economic benefits offered by natural medicines, however, may not end at those who rely on them to treat day-to-day ailments.
The corner of Madagascar that Golden studied contains nearly one percent of all the global floral biodiversity, meaning the chance that a novel pharmaceutical might be developed based on the traditional medicines used in the area is relatively high. The value of that drug, Golden said, could range from $300 million to as much as $5.7 billion.
"That raises additional issues, about who benefits from the discovery of these drugs," Golden said. "In the case of the Madagascar Periwinkle, which was used to develop the treatment for childhood leukemia, a foreign drug company came, took the plants to a foreign lab and they are now making billions, but not five cents has made its way back to Madagascar."
While the question of their medical efficacy is still to be answered, Golden knows first-hand why people continue to rely on traditional medicines in at least some cases, they work.
"I have been living here long enough that I've used some of these remedies myself," Golden said. "In one case, some scratches on my leg got infected, and it blew up like a watermelon from my knee to my ankle. My host family went into the forest and came back with what looked like nettles and put them on my leg. It was incredibly itchy, but the swelling went away completely and the pain disappeared. So these treatments really can work."
Journal reference: PLoS ONE
Provided by Harvard University
- Briefs: Russia's Golden Telecom ups Rascom stake Nov 29, 2005 | not rated yet | 0
- Hidden hunger from wildlife loss Nov 21, 2011 | not rated yet | 0
- Benefits of working from home depends on family demands Nov 08, 2011 | not rated yet | 0
- Old folk remedy revived: How tansy may be a treatment for herpes Feb 22, 2011 | not rated yet | 0
- Herbal remedies escape EU law Aug 09, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications May 22, 2013 | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications May 22, 2013 | not rated yet | 0
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
4 hours ago | 5 / 5 (1) | 0 |
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
10 hours ago | 5 / 5 (3) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
7 hours ago | 5 / 5 (1) | 0 |
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
4 hours ago | not rated yet | 0
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
8 hours ago | 5 / 5 (2) | 0 |
Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.
5 hours ago | not rated yet | 0